HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV | MicrobiomeTrials← Back to trialsNCT07647432
HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2026-12-01Est. Completion: 2029-12-01
Enrollment target: 17 participants Other microbiome trials you might be interested in
AIDS-Related Diffuse Large B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedLugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8Plasmablastic LymphomaPrimary Effusion Lymphoma
This phase I trial studies the safety and side effects of glofitamab plus a chemoimmunotherapy regimen called R-CHOP (ri…
Multiple LocationsEst. completion Apr 30, 2028
Lymphoma, Primary Effusion
Background:
Primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and Multicentric Castleman Disease (MCD) are…
Bethesda, United StatesEst. completion Aug 1, 2034